HX016-7 / HanX Biopharma - LARVOL DELTA

Discovery of HX016-7, a novel PD-L1 x VEGF BsAb, as a new candidate treatment of solid tumors (AACR 2025) - "A first-in-class PD-L1xVEGF bispecific antibody (BsAb), BNT327/PM8002, has demonstrated promising efficacy in treating TNBC and NSCLC cancers in advance stage of clinical development, which prompted us to engineer a novel and potentially best-in-class (BIC) PD-L1xVEGF BsAb by using a validated anti-PD-L1 and a novel anti-VEGF (HX006, a novel VEGF mAb with more favor activity over Avastin) mAb sequences. In a subcutaneous A549 non-small-cell lung cancer (NSCLC) cell-derived xenograft model in immunocompromised mice, HX016-7 also showed slightly stronger anti-tumor activity over BNT327/PM8002, which can be attributed to anti-VEGF function. We believe these preclinical data warrants the candidacy of HX016-7 to be further developed for the treatment of solid tumors."

Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting (PRNewswire) - "Hanx Biopharmaceuticals Ltd...highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago (April 25–30). The presentations spotlighted novel bispecific antibodies and a CSF-1R inhibitor, underscoring the company's leadership in innovative cancer treatment strategies."

Clinical data • Solid Tumor